SAM
GNOM icon

Strive Asset Management’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

Strive Asset Management’s Portfolio GNOM Stock Details GNOM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-7,945
Closed -$253K – 90
2025
Q1 		$253K Sell
7,945
-2,592
-25% -$98.4K 0.18% 105
2024
Q4 		$409K Buy
+10,537
New +$443K 0.31% 88

Other funds holding GNOM

FTUS
Flow Traders U.S. New York $2.43B AUM 44.44% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
OAM
Oppenheimer Asset Management New York $9.63B AUM 30.32% 1-Year Est. Return
IWM
IHT Wealth Management Chicago, Illinois $4.7B AUM 25.67% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
IA
Insight Advisors Newtown, Pennsylvania $567M AUM 25.52% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return
OCM
One Capital Management Westlake Village, California $3.6B AUM 16.02% 1-Year Est. Return

Strive Asset Management's GNOM Position: Q2 2025 in Review

Strive Asset Management sold out of Global X Genomics & Biotechnology ETF (GNOM) in Q2 2025, closing a stake of 7,945 shares — an estimated $253K sold.

Strive Asset Management first reported a position in GNOM in Q4 2024 and held it in 2 quarters. The position peaked at $409K in Q4 2024. 53 funds tracked by Wall St. Rank hold GNOM as of Q2 2025.

  • Strive Asset Management reported no remaining Global X Genomics & Biotechnology ETF position as of Q2 2025 after selling out during the quarter.
  • Strive Asset Management sold 7,945 Global X Genomics & Biotechnology ETF shares in Q2 2025, an estimated $253K.
  • Strive Asset Management first reported a position in Global X Genomics & Biotechnology ETF in Q4 2024 and held it in 2 quarters.
  • Strive Asset Management's Global X Genomics & Biotechnology ETF position peaked at $409K in Q4 2024.
  • 53 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q2 2025.

Based on Strive Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.